Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2000-11-14
2002-05-14
McKelvey, Terry (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
Reexamination Certificate
active
06387649
ABSTRACT:
The present invention relates to the use of the E region of the transcription factor DP-3 as a target for novel assays and its use as a nuclear localisation signal.
The orderly progress of cells through the cell cycle involves a number of control points which assess the status of the intracellular and extracellular environment. A major control point, occurring as cells enter S phase, involves the cellular transcription factor E2F, a molecular implicated in the regulation of S phase gene expression (Nevins, 1992; La Thangue, 1994; Müller, 1995; Weinberg, 1995). An important for E2F in early cell cycle control is suggested by the nature of the proteins which influence its transcriptional activity. for example, members of the group of pocket proteins, exemplified by the retinoblastoma tumour suppressor gene product (pRb), repress the transcriptional activity of E2F (Hiebert et al., 1992: Zamanian and La Thangue, 1992; 1993; Schwarz et al., 1993; Wolf et al., 1995). The ability to repress E2F correlates with the capacity of pRb, or its relatives, to negatively regulate early cell cycle progression (Hiebert et al., 1992; Zamanian and Le Thangue, 1992; Hinds et al., 1992; Zhe et al., 1995; 1995a). Furthermore, growth arrest caused by high level expression of pRb can be overcome by increasing the level of E2F (Zhu et al., 1993), implying than E2F is a principal physiological target through which pRb exerts its effects on the cell cycle. Another groups of molecules which regulate cell cycle transitions, the cyclins and their associated catalytic regulatory subunits, also interact with and control the activity of E2P (Bandara et al., 1991; Lees et al., 1992; Zhu et al., 1995b). Cyclins A. E. and D together with an appropriate catalytic subunit can influence the biological activity of pocket proteins (Hinds et al., 1992; Dowdy et al., 1993; Ewen et al., Sherr, 1993), and direct phosphorylation by cyclinA-cdk2 is believed to interfere with the DNA binding activity of E2F (Krek et al., 1994; 1995).
The physiological regulation of E2F activity imparted by these afferent signalling proteins can be subverted by viral oncoproteins, such as adenovirus E1a, human papilloma virus E7 and SV40 large T antigen, through their ability to release active E2F by sequestering pocket proteins and cyclin/cdk complexes (Bandara and La Thange, 1991; Chellappan et al., 1991; 1992; Morris et al., 1993). This property correlates with the ability of these viral oncoproteins to transform tissue culture cells, again implicating E2F as an important physiological target in virally-medicated oncogensis.
Considerable progress has been made in elucidating the composition of E2F. It is now known the E2F DNA binding activity defined in mammalian cells extracts is a generic activity caused by an array of DNA binding heterodimers made up from two distinct families of proteins, known as E2F and DP (La Thangue, 1994). Five members of the E2F family, from E2F-1 to E2F-5, have been isolated, each protein possessing preferential specificity for pocket proteins (Helin et al., 1992; Kaelin et al., 1992; Shan et al 1992; Ivey-Hoyle et al., 1993; Lees et al., 1993; Beijersbergen et al., 1994; Ginsberg et al., 1994; Buck et al., 1995; Hijmans et al., 1995; Sardet et al., 1995). For example, E2F-1 is regulated by pRb, and E2F-4 by p107 and p130 (Helin et al., 1993a; Flemington et al., 1993; Beijersbergen et al., 1994; 1995; Ginsberg et al., 1994; Vairo et al., 1995). Three members of the DP family are known (Girling et al., 1993; 1994; Ormondroyd et al., 1995; Wu et al., 1995; Zhang and Chellappan, 1995), DP-1 being a widespread and constitutive component of physiological E2F during cell cycle progression in some cell types (Girling et al., 1993; Bandara et al., 1994). Supporting their role as dominant regulators of the cell cycle, both E2F and DP proteins have been shown to possess proto-oncogenic activity (Johnson et al., 1994; Jooss et al., 1995).
Our previous characterisation of DP-3 indicated that it is a novel member of the DP family of proteins and that its RNA undergoes extensive alternative splicing (Ormondroyd et al., 1995). Processing events in the 5′ untranslated region and coding sequence of the RNA give rise to a rage of products present in both cell lines and tissues (Ormondroyd et al., 1995). A sequence of 16 amino acid resides within the N-terminal region of the DNA binding domain, known as the E region, is one such region subject to the alternative splicing of DP-3 RNA. Further, in the four DP-3 protein products which have been characterised, &agr; and &dgr; constitute E- forms, whereas &bgr; and &ggr; are E- variants (Ormondroyd et al., 1995). although E-; extensive sequence conservation is apparent across the DP protein family, a comparison of the known DP protein sequences indicated that they fall into two categories, being either E- or for example, DP-1 is an E-variant.
REFERENCES:
patent: 5859199 (1999-01-01), La Thangue et al.
patent: 6159691 (2000-12-01), La Thangue et al.
patent: WO 93/15227 (1993-08-01), None
patent: WO 63/23539 (1993-11-01), None
patent: WO 94/10307 (1994-05-01), None
patent: WO 94/12521 (1994-06-01), None
patent: WO 96/01425 (1996-01-01), None
patent: WO 97/02354 (1997-01-01), None
patent: WO 97/43647 (1997-11-01), None
Magae et al., Journal of Cell Science, vol. 109, pp. 1717-1726.
Ngo et al., “The Protein Folding Problem and Tertiary Structure Prediction”, 1994, Mertz et al. (eds), Birkhauser, Boston, MA, pp. 433 and 492-495.
Altmann et al , TIBS 18 11/93, pp. 429 -432.
Bandara et al, The EMBO Journal of vol. 12 No. 11 pp. 4317-4324 1993.
Bandara , The EMBO Journal vol. 13 No. 13, pp. 3104-3114, 1994.
Beijersbergen et al , Genes & Development 8:2680-2690 pp. 2680-2690.
Boulikas , J. Cellular Biochemistry 55:32-58 1994.
Boulikas , Critical Reviews in Eukaryotic Gene Expression, 3(3):193-227 (1993).
Buck et al , Oncogene (1995) 11, 31-38.
Chang et al , J. of Virology 1995 vol. 69 No. 2 pp. 801-808.
Cobrinik et al, Genex & Development 7:2392-2404 1993.
Descombes et al , Cell, vol. 67 569-579 Nov. 1991.
Dingwall et al , TIBS 16 12/91 4780481.
Dynlacht et al , Genes & Development 1994 pp. 1772-1786.
Fields et al , Letters to Nature vol. 340 pp. 245-246 1989.
Flemington et al , Proc. Natl. Acad. Sci. USA vol. 90 pp. 6914-6918 1993.
Geballe et al , TIBS 19 1994 pp. 159-164.
Ginsberg et al , Genes & Development 8:2665-2679 1994.
Girling et al , Nature vol. 362 1993 pp. 83-87.
Girling et al , Molecular Biology of the Cell vol. 5, 1081-1092, 1994 pp. 1081-1092.
Helin et al , Cell vol. 70, 337-350 1992.
Helin et al , Genes & Development 7:1850-1861 1993.
Molecular and Cell Biology vol. 13, No. 10, 1993 p. 6501-6508.
Hiebert et al., Gene & Development 6:177-185 1992.
Hill et al., J. Biological Chemistry 1993 vol. 268, No. 1, Jan 5 issue pp. 726-731.
Hill et al., Cell 1995 pp. 199-211.
Hoyle et al., Molecular and Cellular Biology vol. 13, No. 12 1993, pp. 7802-7812.
Kaeline et al., vol. 70, pp. 351-364, 1992.
Kozak , Nucleic Acids Research vol. 15, No. 10 1987 pp. 8125-8148.
Krek et al., Cell vol. 78 161-172 1994.
Krek et al., Science vol. 262 1993 pp. 1557-1560.
La Thangue., TIBS 19 1994 pp. 108-114.
Lam et al., Current Opinion in Cell Biology 1994, 6:859-866.
Ormondroyd et al., Oncogene 1995, 11, 1437-1446.
Lees et al., Molecular and Cellular biology, 1993, pp. 7813-7825.
Lees et al., Genes & Development 6:1874-1885.
Li et al., Genes & Development 1993 pp. 2366-2377.
Science vol. 258, 1992 Nevins E2F: A Link between the Rb Tumor Suppressor Protein and Viral Oncoproteins.
Schwarz et al. “Interactions of the p107 and Rb proteins . . . ” The EMBO Journal vol. 12 No. 3 pp. 1013-1020 1993.
Bei Shan et al. “Molecular Cloning of Cellular Genes . . . ” Molecular and Cellular Biology 1992 vol. 12, pp. 5620-5631.
Shirodkar “The Transcription Factor E2F Interacts with the Retinoblastoma Product..” Cell vol. 68, 157-166. 1992.
Smith et al. “Single step purification of polypeptides expressed inEscherichia coli. . . ” Gene 67 1988 31-40.
Treacy et al, “Twin of I-POU: A Two Amino Acid Difference int he
De La Luna Susana
La Thangue Nicholas B.
McKelvey Terry
Prolifix Limited
LandOfFree
Assay for a regulator of cell cycle progression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay for a regulator of cell cycle progression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay for a regulator of cell cycle progression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2873546